title: A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers.
abstract: BACKGROUND
  Tenatoprazole is a novel proton pump inhibitor with a seven-hour plasma half-life.
  
  
  OBJECTIVE
  To compare the effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric acidity during the first 48 h in healthy volunteers.
  
  
  METHODS
  This randomized two-period crossover study included 24 Helicobacter Pylori-negative subjects; tenatoprazole 40 mg or esomeprazole 40 mg daily were given before breakfast for two consecutive days, with a 2-week wash-out between the administration periods. Intragastric pH was monitored for 48 h.
  
  
  RESULTS
  Over 48 h, tenatoprazole 40 mg exerted a more potent acid inhibition than esomeprazole 40 mg (median pH: 4.3 vs. 3.9, P < 0.08; per cent of time above pH 4: 57% vs. 49%, P < 0.03; proportion of subjects with at least half of the time above pH 4: 71% vs. 46%). These differences resulted from better night-time acid control with tenatoprazole 40 mg than esomeprazole 40 mg (first night median pH: 4.2 vs. 2.9, P < 0.0001; second night: 4.5 vs. 3.2, P < 0.0001). The duration of nocturnal acid breakthroughs was significantly reduced during both nights. In contrast, no significant difference was detected during the daytime periods between both regimens.
  
  
  CONCLUSIONS
  Over the first 48 h, tenatoprazole 40 mg achieves a better overall and night-time control of gastric pH than esomeprazole 40 mg. The translation of better early control of acidity into clinical benefits deserves further studies.
authors.affiliation: CIC-INSERM-CHU de Nantes, France. jeanpaul.galmiche@chu-nantes.fr
authors.forename: J P
authors.initials: JP
authors.lastname: Galmiche
authors.forename: S
authors.initials: S
authors.lastname: Sacher-Huvelin
authors.forename: S
authors.initials: S
authors.lastname: Bruley des Varannes
authors.forename: F
authors.initials: F
authors.lastname: Vavasseur
authors.forename: A
authors.initials: A
authors.lastname: Taccoen
authors.forename: P
authors.initials: P
authors.lastname: Fiorentini
authors.forename: M
authors.initials: M
authors.lastname: Homerin
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D018592:Cross-Over Studies; D064098:Esomeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D054328:Proton Pump Inhibitors; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D007093:Imidazoles; D054328:Proton Pump Inhibitors; D011725:Pyridines; D064098:Esomeprazole; C119998:Tenatoprazole